Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 134,689 shares of the company’s stock, valued at approximately $954,000.

Other large investors have also added to or reduced their stakes in the company. Assetmark Inc. raised its holdings in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after acquiring an additional 1,552 shares in the last quarter. Ausdal Financial Partners Inc. purchased a new position in shares of Bicycle Therapeutics in the second quarter valued at $70,000. Pinnacle Wealth Management Advisory Group LLC purchased a new position in shares of Bicycle Therapeutics in the fourth quarter valued at $71,000. Sei Investments Co. bought a new stake in Bicycle Therapeutics in the second quarter worth $74,000. Finally, Ameriprise Financial Inc. purchased a new stake in Bicycle Therapeutics during the second quarter valued at $86,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Up 0.7%

Bicycle Therapeutics stock opened at $4.45 on Friday. Bicycle Therapeutics PLC Sponsored ADR has a 12-month low of $4.24 and a 12-month high of $9.36. The firm has a 50-day moving average price of $4.80 and a 200-day moving average price of $5.87. The firm has a market capitalization of $310.21 million, a PE ratio of -1.41 and a beta of 1.56.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.25). Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $7.50 million. As a group, sell-side analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -1.98 earnings per share for the current fiscal year.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 5,967 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total value of $29,297.97. Following the sale, the chief executive officer directly owned 613,029 shares in the company, valued at approximately $3,009,972.39. This represents a 0.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 9,992 shares of company stock worth $49,363 over the last quarter. Corporate insiders own 22.90% of the company’s stock.

Analysts Set New Price Targets

BCYC has been the subject of several research reports. Needham & Company LLC lowered their price objective on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Morgan Stanley lowered their price target on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a report on Wednesday, April 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, April 10th. Wall Street Zen lowered Bicycle Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 10th. Finally, Citizens Jmp dropped their target price on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a report on Wednesday, March 18th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $14.00.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.